share_log

Eli Lilly and Co | 8-K: Chief Financial Officer Anat Ashkenazi Resigns

Eli Lilly and Co | 8-K: Chief Financial Officer Anat Ashkenazi Resigns

礼来 | 8-K：首席财务官Anat Ashkenazi辞职
美股sec公告 ·  06/05 07:51
Moomoo AI 已提取核心信息
Eli Lilly and Company, a leading pharmaceutical firm, announced on June 5, 2024, that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to pursue a new career opportunity outside of the pharmaceutical industry. Ashkenazi, who has been with Eli Lilly for 23 years, will continue her duties and remain a member of the Executive Committee until July 2024. During her tenure as CFO, the company experienced significant growth and established a foundation for future success. Prior to her role as CFO, Ashkenazi held various financial leadership positions within the company, including senior vice president and controller of Lilly Research Laboratories. Eli Lilly has commenced both internal and external searches to find Ashkenazi's successor. The announcement was made through a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
Eli Lilly and Company, a leading pharmaceutical firm, announced on June 5, 2024, that Anat Ashkenazi has resigned from her position as Chief Financial Officer (CFO) to pursue a new career opportunity outside of the pharmaceutical industry. Ashkenazi, who has been with Eli Lilly for 23 years, will continue her duties and remain a member of the Executive Committee until July 2024. During her tenure as CFO, the company experienced significant growth and established a foundation for future success. Prior to her role as CFO, Ashkenazi held various financial leadership positions within the company, including senior vice president and controller of Lilly Research Laboratories. Eli Lilly has commenced both internal and external searches to find Ashkenazi's successor. The announcement was made through a press release attached as Exhibit 99.1 to the company's Current Report on Form 8-K filed with the SEC.
药品企业领军公司礼来公司于2024年6月5日宣布，Anat Ashkenazi因追求药品行业外的新职业机会而辞去了其首席财务官（CFO）的职务。Ashkenazi已在礼来公司工作23年，在2024年7月之前将继续履行职责并保留执行委员会成员的身份。在她担任财务首席官期间，公司经历了重大增长并为未来的成功奠定了基础。在担任首席财务官之前，Ashkenazi在公司内担任过各种财务领导职位，包括礼来研究实验室的高级副总裁和控制器。礼来公司已经开始内部和外部寻找Ashkenazi的继任者。该公告通过附在8-K表格上的附件99.1的新闻稿发布。
药品企业领军公司礼来公司于2024年6月5日宣布，Anat Ashkenazi因追求药品行业外的新职业机会而辞去了其首席财务官（CFO）的职务。Ashkenazi已在礼来公司工作23年，在2024年7月之前将继续履行职责并保留执行委员会成员的身份。在她担任财务首席官期间，公司经历了重大增长并为未来的成功奠定了基础。在担任首席财务官之前，Ashkenazi在公司内担任过各种财务领导职位，包括礼来研究实验室的高级副总裁和控制器。礼来公司已经开始内部和外部寻找Ashkenazi的继任者。该公告通过附在8-K表格上的附件99.1的新闻稿发布。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息